A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT).
Martin Schlumberger
Consultant or Advisory Role - AstraZeneca; Bayer; Eisai; Genzyme/Sanofi
Honoraria - AstraZeneca; Bayer; Eisai; Genzyme/Sanofi; SOBI
Research Funding - AstraZeneca; Bayer; Eisai; Genzyme/Sanofi
Makoto Tahara
Consultant or Advisory Role - Eisai; Merck Serono
Honoraria - Bristol-Myers Squibb; Merck Serono
Research Funding - Boehringer Ingelheim; Eisai
Lori J. Wirth
No relevant relationships to disclose
Bruce Robinson
Consultant or Advisory Role - AstraZeneca; Bayer; Eisai
Honoraria - AstraZeneca; Bayer; Eisai
Marcia S. Brose
Consultant or Advisory Role - Eisai
Research Funding - Eisai
Rossella Elisei
Consultant or Advisory Role - AstraZeneca; Bayer; Genzyme
Honoraria - AstraZeneca; Bayer; Genzyme
Corina E. Dutcus
Employment or Leadership Position - Eisai
BegoƱa de las Heras
Employment or Leadership Position - Eisai
Junming Zhu
Employment or Leadership Position - Eisai
Mouhammed Amir Habra
No relevant relationships to disclose
Kate Newbold
No relevant relationships to disclose
Manisha H. Shah
Consultant or Advisory Role - Exelixis
Research Funding - Bayer; Eisai; Exelixis
Ana O. Hoff
Research Funding - Eisai
Andrew G Gianoukakis
Research Funding - Eisai
Naomi Kiyota
Honoraria - Eisai
Research Funding - Eisai
Matthew Hiram Taylor
No relevant relationships to disclose
Sung-Bae Kim
Consultant or Advisory Role - Novartis (U)
Research Funding - II Dong Pharmaceuticals; Novartis
Monika K Krzyzanowska
Consultant or Advisory Role - Bayer/Onyx (U)
Honoraria - AstraZeneca; Novartis; Sanofi
Research Funding - AstraZeneca; Eisai; Exelixis; Novartis
Steven I. Sherman
Consultant or Advisory Role - Amgen; AstraZeneca; Bayer; Eisai; Exelixis; Pfizer; Roche
Honoraria - Exelixis; Onyx
Research Funding - Amgen
Other Remuneration - Exelixis